Accretion Pharmaceuticals, a Gujarat-based pharma manufacturer, concluded its SME IPO with a strong subscription of 7.31 times. The IPO, priced at Rs 96-101 per share, aims to utilize proceeds for capital expenditures and facility upgrades. Despite robust financial growth and international presence, the grey market premium remained flat, indicating market caution ahead of its NSE SME platform listing.
Pankaj Tibrewal sees stronger top-line growth driving India’s next earnings cycle
Indian companies are poised to navigate input cost pressures and sustain growth, with the upcoming earnings season expected to be the next market trigger. Experts